Table 3

Breast cancer risk in relation to CYP17 genotype, stratified by histopathological type, menopausal hormones or diabetes mellitus

CYP17 genotype

P for interaction

A1/A1

A1/A2

A2/A2

Cases/controls^a

OR^b(CI)

Cases/controls^a

OR^b(CI)

Cases/controls^a

OR^b(CI)

All cancers

550/488

1 (reference)

711/638

1.0 (0.9–1.2)

238/212

1.0 (0.8–1.3)

Ductal cancers

420/488

1 (reference)

510/638

1.0 (0.8–1.1)

180/212

1.0 (0.8–1.3)

Lobular cancers

56/488

1 (reference)

90/638

1.3 (0.9–1.8)

24/212

1.1 (0.6–1.8)

Duration of menopausal hormone use(all cancers)

Never

390/370

1 (reference)

469/473

0.9 (0.8–1.1)

165/154

1.0 (0.8–1.3)

Any kind

<4

59/50

1 (reference)

96/74

1.2 (0.7–2.0)

26/25

1.0 (0.5–2.1)

≥4

101/68

1 (reference)

146/91

1.2 (0.8–1.9)

47/33

1.0 (0.6–1.7)

0.668

Estrogen only

<4

28/22

1 (reference)

43/33

1.1 (0.5–2.3)

7/11

0.6 (0.2–1.8)

≥4

39/23

1 (reference)

42/30

1.0 (0.5–2.1)

15/13

0.7 (0.3–1.9)

0.703

Estrogen + progestin

<4

42/41

1 (reference)

75/66

1.2 (0.7–2.1)

23/21

1.2 (0.6–2.5)

≥4

64/47

1 (reference)

108/62

1.3 (0.8–2.2)

34/20

1.2 (0.6–2.4)

0.723

Self-reported diabetes mellitus (all cancers)

No

502/448

1 (reference)

644/592

1.0 (0.8–1.2)

217/194

1.0 (0.8–1.3)

Yes

48/40

1 (reference)

67/46

1.3 (0.7–2.2)

21/18

1.1 (0.5–2.3)

0.259

^aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. ^bAnalyses were conditioned on age (5-year age groups), menopausal estrogen only use (never, <4 years or ≥4 years), use of estrogen in combination with progestin (never, <4 years or ≥4 years) and diabetes mellitus (yes or no). CI, confidence interval; OR, odds ratio.

Einarsdóttir et al. Breast Cancer Research 2005 7:R890   doi:10.1186/bcr1319